Open-label phase IIa trial of CYT 003 QbG10 monotherapy in patients with mild to moderate seasonal allergic rhinitis due to grass pollen allergy.

Trial Profile

Open-label phase IIa trial of CYT 003 QbG10 monotherapy in patients with mild to moderate seasonal allergic rhinitis due to grass pollen allergy.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2006

At a glance

  • Drugs CMP 001 (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Cytos Biotechnology
  • Most Recent Events

    • 14 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top